Changing epidemiology of serious bacterial infections in febrile infants without localizing signs.
Repository Usage Stats
OBJECTIVE: Historically, management of infants with fever without localizing signs (FWLS) has generated much controversy, with attempts to risk stratify based on several criteria. Advances in medical practice may have altered the epidemiology of serious bacterial infections (SBIs) in this population. We conducted this study to test the hypothesis that the rate of SBIs in this patient population has changed over time. PATIENTS AND METHODS: We performed a retrospective review of all infants meeting FWLS criteria at our institution from 1997-2006. We examined all clinical and outcome data and performed statistical analysis of SBI rates and ampicillin resistance rates. RESULTS: 668 infants met criteria for FWLS. The overall rate of SBIs was 10.8%, with a significant increase from 2002-2006 (52/361, 14.4%) compared to 1997-2001 (20/307, 6.5%) (p = 0.001). This increase was driven by an increase in E. coli urinary tract infections (UTI), particularly in older infants (31-90 days). CONCLUSIONS: We observed a significant increase in E. coli UTI among FWLS infants with high rates of ampicillin resistance. The reasons are likely to be multifactorial, but the results themselves emphasize the need to examine urine in all febrile infants <90 days and consider local resistance patterns when choosing empiric antibiotics.
Drug Resistance, Bacterial
Published Version (Please cite this version)10.1371/journal.pone.0012448
Publication InfoWatt, Kevin; Waddle, Erica; & Jhaveri, Ravi (2010). Changing epidemiology of serious bacterial infections in febrile infants without localizing signs. PLoS One, 5(8). pp. e12448. 10.1371/journal.pone.0012448. Retrieved from https://hdl.handle.net/10161/4568.
This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.
More InfoShow full item record
Associate Professor of Pediatrics
Dr. Watt’s career goal is to advance public health by integrating physiology and pharmacology into approaches for designing and conducting early-phase trials in critically ill children. His current efforts focus on the use of physiologically-based pharmacokinetic modeling and simulation to understand drug disposition in children on extracorporeal life support. His research is supported by the NICHD-sponsored Pediatric Critical Care Scientist Development Program and a NICHD-sponsored Car